BRIEF-Calcimedica Announces Clinical Development Of Auxora May Proceed Following FDA Review Of Kourage Trial Interim Safety Data

CalciMedica, Inc.

CalciMedica, Inc.

CALC

0.00

June 24 (Reuters) - CalciMedica Inc CALC.O:

  • CALCIMEDICA ANNOUNCES CLINICAL DEVELOPMENT OF AUXORA MAY PROCEED FOLLOWING FDA REVIEW OF KOURAGE TRIAL INTERIM SAFETY DATA

  • CALCIMEDICA - FDA REVIEW ALLOWS CALCIMEDICA TO CONTINUE DOSING AUXORA IN KOURAGE TRIAL

  • CALCIMEDICA - FDA PROVIDES NO COMMENTS, CALCIMEDICA TO CONTINUE AUXORA DEVELOPMENT ACROSS INDICATIONS

  • CALCIMEDICA - EXPECTS FDA FEEDBACK ON AUXORA PANCREATITIS PROGRAM IN Q3 2026

Source text: ID:nPn1Z4LB7a

Further company coverage: CALC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.